Studies have shown a link between homocysteine (Hcy) and heart diseases, kidney diseases, cerebrovascular diseases, liver diseases, and other pathological conditions. However, the relationship between Hcy and liver fibrosis (LF) is unclear. Here, we studied the link between plasma Hcy concentration and LF. Methods: We determined and recorded the plasma Hcy concentration, general biochemical parameters,… Continue reading Plasma Levels of #Homocysteine is Associated with Liver #Fibrosis in Health Check-Up Population
Category: Hepatology
#NONALCOHOLIC FATTY LIVER DISEASE-RELATED RISK OF #CARDIOVASCULAR DISEASE AND OTHER CARDIAC COMPLICATIONS
Nonalcoholic fatty liver disease (NAFLD) affects approximately ~25% of the global adult population. The aim of this narrative review is to describe the associations between NAFLD and cardiovascular disease (CVD), arrhythmias, cardiac conduction defects, myocardial remodelling and heart failure. We also discuss the potential mechanisms that mediate or attenuate the strength of these associations, and… Continue reading #NONALCOHOLIC FATTY LIVER DISEASE-RELATED RISK OF #CARDIOVASCULAR DISEASE AND OTHER CARDIAC COMPLICATIONS
The changing characteristics of patients infected with chronic hepatitis #C virus from 2014 to 2019: Real-world data from the German #Hepatitis C-Registry (DHC-R)
The number of patients diagnosed with hepatitis C virus (HCV) is markedly higher than the number initiating treatment indicating gaps in the care cascade, likely centered around reaching at-risk populations. Understanding changing characteristics of patients with HCV allows for targeted programs that increase linkage to care. We investigated changes in demographic and clinical characteristics of… Continue reading The changing characteristics of patients infected with chronic hepatitis #C virus from 2014 to 2019: Real-world data from the German #Hepatitis C-Registry (DHC-R)
Safety and Efficacy of amplitude-modulated radiofrequency electromagnetic fields in advanced #hepatocellular carcinoma
Importance: Hepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide. Despite the recent approval of several new agents, long-term disease control remains elusive for most patients. Administration of 27.12 MHz radiofrequency (RF) electromagnetic fields (EMF) by means of a spoon-shaped antenna (TheraBionic P1 device) placed on the anterior part of the tongue… Continue reading Safety and Efficacy of amplitude-modulated radiofrequency electromagnetic fields in advanced #hepatocellular carcinoma
#EGFR activation limits the response of #liver cancer to lenvatinib
Hepatocellular carcinoma (HCC)—the most common form of liver cancer—is an aggressive malignancy with few effective treatment options1. Lenvatinib is a small-molecule inhibitor of multiple receptor tyrosine kinases that is used for the treatment of patients with advanced HCC, but this drug has only limited clinical benefit2. Here, using a kinome-centred CRISPR–Cas9 genetic screen, we show… Continue reading #EGFR activation limits the response of #liver cancer to lenvatinib
Effects of #Tamoxifen vs. Toremifene on #fatty liver development and lipid profiles in #breast Cancer
Tamoxifen (TAM) and Toremifene (TOR), two kinds of selective estrogen receptor modulators (SERMs), have equal efficacy in breast cancer patients. However, TAM has been proved to affect serum lipid profiles and cause fatty liver disease. The study aimed to compare the effects of TAM and TOR on fatty liver development and lipid profiles. MethodsThis study… Continue reading Effects of #Tamoxifen vs. Toremifene on #fatty liver development and lipid profiles in #breast Cancer
Immunotherapy-based targeting of MSLN+ activated portal #fibroblasts is a strategy for treatment of cholestatic liver #fibrosis
Mesothelin (Msln) expression is increased in tissue fibroblasts of damaged liver and other organs and Msln is a common mediator of liver, lung, and kidney fibrosis. We show that anti-Msln immunotoxins kill the Msln-expressing fibroblasts and reduce collagen type I deposition in fibrotic liver, indicating that agents that specifically kill Msln-expressing cells should be a… Continue reading Immunotherapy-based targeting of MSLN+ activated portal #fibroblasts is a strategy for treatment of cholestatic liver #fibrosis
Auto-immune #hepatitis following #COVID vaccination
Unprecedented loss of life due to the COVID pandemic has necessitated the development of several vaccines in record time. Most of these vaccines have received approval without being extensively whetted for their adverse effect and efficacy profiles. Most adverse effects have been mild, nonetheless, more serious thromboembolic events have also been reported. Autoimmune hepatitis (AIH)… Continue reading Auto-immune #hepatitis following #COVID vaccination
Incidence of #liver-related morbidity and mortality in a population cohort of non-alcoholic fatty liver disease
Non-alcoholic fatty liver disease (NAFLD) increases morbidity and mortality. However, patients in biopsy-based cohorts are highly selected and the absolute risks of liver- and non-liver outcomes in NAFLD in population remains undefined. We analyzed both liver-related and non-liver-related outcomes in Finnish population cohorts of NAFLD. MethodsWe included 10993 individuals (6707 men, mean age 53.3±12.6 years)… Continue reading Incidence of #liver-related morbidity and mortality in a population cohort of non-alcoholic fatty liver disease
2 Medical News 